The Densities of T Cells, Langerhans Cells, and Natural Killer Cells in Uninvolved Skin of Patients with Acne Vulgaris

    September 1997 in “ Journal of the European Academy of Dermatology and Venereology ”
    A. Burhan Aksakal, Ayla Gülekon, Özlem Altay, Cem Sezer, Murat Orhan Öztaş
    Image of study
    TLDR People with acne have more CD4+ immune cells in their skin than healthy people.
    The study investigated the presence of various immune cells in the skin of patients with Acne Vulgaris (AV) compared to healthy controls. The researchers examined 25 biopsies, with 10 from moderate to severe acne cases and 15 from healthy subjects. They looked for the density of CD3+ (total T lymphocytes), CD4+ (helper/inducer T lymphocytes), CD8+ (suppressor/cytotoxic T lymphocytes), CD1a+ (Langerhans cells), and CD56+ (Natural Killer cells) in the epidermis and dermis using immunocytochemical methods. The results showed that only the CD4+ cells were statistically significantly elevated in the dermis of patients with AV compared to healthy subjects, with a p-value less than 0.05.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 878 results
      If You Have DUPA, PLEASE READ THIS: Everyone Should Be Scalp Biopsied

      community If You Have DUPA, PLEASE READ THIS: Everyone Should Be Scalp Biopsied

      in Research  830 upvotes 1 year ago
      Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.

      community EMA is re-examining Winlevi (clascoterone at lower concentration)

      in Treatment  7 upvotes 6 months ago
      Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

      community Why Breezula Won’t Work for Everyone.

      in Chat  29 upvotes 6 days ago
      Breezula, a new topical hair loss treatment, is expected to be expensive, with an estimated cost of €300 per month, making it less accessible compared to cheaper alternatives like finasteride. Some users discuss the potential for cheaper generics from countries like China and India, while others debate the effectiveness and pricing strategy of Breezula compared to other treatments like minoxidil and RU58841.

    Similar Research

    5 / 1000+ results